Recent Investment Analysts’ Ratings Updates for GeneDx (WGS)

Several analysts have recently updated their ratings and price targets for GeneDx (NASDAQ: WGS):

• 8/8/2026 – GeneDx was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/4/2026 – GeneDx was upgraded by Weiss Ratings from “sell (e+)” to “sell (d)”.
• 8/4/2026 – GeneDx had its price target raised by Canaccord Genuity Group Inc. from $75.00 to $90.00. They now have a “buy” rating on the stock.
• 8/4/2026 – GeneDx had its “buy” rating reaffirmed by BTIG Research. They now have a $90.00 price target on the stock.
• 7/28/2026 – GeneDx was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/15/2026 – GeneDx had its “buy” rating reaffirmed by TD Cowen.
• 6/29/2026 – GeneDx had its “buy” rating reaffirmed by Guggenheim. They now have a $74.00 price target on the stock, up from $70.00.
• 6/29/2026 – GeneDx was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/23/2026 – GeneDx had its “overweight” rating reaffirmed by Piper Sandler. They now have a $63.00 price target on the stock, up from $50.00.

Insider Activity at GeneDx

In other news, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total transaction of $638,145.77. Following the transaction, the chief executive officer directly owned 104,372 shares of the company’s stock, valued at $6,342,686.44. This trade represents a 9.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,729 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total transaction of $226,611.33. Following the completion of the transaction, the chief financial officer directly owned 39,954 shares of the company’s stock, valued at $2,428,004.58. This trade represents a 8.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders bought 700,000 shares of company stock worth $32,569,650 and sold 19,135 shares worth $1,128,499. Corporate insiders own 25.17% of the company’s stock.

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.